AstraZeneca will manufacture up to 30 million doses of Oxford University’s coronavirus vaccine by September if trials show it to be effective — and 100 million doses for global deployment by year’s end, the UK’s Secretary of State for Business Alok Sharma has announced. Read More

Moderna has reported positive early results from a phase 1 trial of its COVID-19 vaccine candidate, mRNA-1273, with all participants producing antibodies to the virus within 15 days of a single dose. It hopes to launch a phase 3 trial in July in an extremely expedited time frame. Read More

The National Institutes of Health (NIH)’s public-private partnership to work on COVID-19 has decided on six existing treatments to evaluate in trials later this month, and said it looks to have vaccine candidates ready for trials by the start of July. Read More

The company plans to accelerate marketing of its test in North America. Read More

Drawing blood from veins is less painful for patients and requires less training. Read More

A new study in France has found that hydroxychloroquine provides no benefit for COVID-19 patients, adding to the growing evidence that the anti-malaria drug has little value as a coronavirus treatment. Read More